Jan 11, 2022 / 04:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. This is Rachel Vatnsdal from our life science tools and diagnostics team here at JPMorgan. It's my pleasure to introduce our next company, PerkinElmer. And as a reminder, if you have any questions, please submit them through the Q&A function on our conference website.
And with that, I will turn it over to Prahlad.
Prahlad R. Singh - PerkinElmer, Inc. - CEO, President & Director
Welcome, everyone. Thank you, JPMorgan, for the opportunity to provide an update on the progress we've been making on the transformation of the business. While in 2019 and 2020, we really started to transform the business internally. Looking back, I think 2021 will be marked as a year that we were able to really accelerate our shift into faster-growing markets, which will continue to benefit the company in the years to come.
Before we start, please read the safe harbor statement and consult our website for additional disclosures regarding any forward
PerkinElmer Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers